vs
BK Technologies Corp（BKTI）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是BK Technologies Corp的1.4倍（$30.3M vs $21.5M），BK Technologies Corp净利率更高（19.7% vs -221.3%，领先241.0%），REGENXBIO Inc.同比增速更快（43.0% vs 20.0%），BK Technologies Corp自由现金流更多（$2.8M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -21.6%）
BK Technologies Corp主要设计、生产和销售模拟及数字双向无线电通信设备及相关配件，核心产品服务于公共安全部门、应急响应人员、政府机构及北美地区商业客户，专注于提供高可靠性的关键任务通信解决方案。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
BKTI vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.4倍
$21.5M
营收增速更快
RGNX
高出23.0%
20.0%
净利率更高
BKTI
高出241.0%
-221.3%
自由现金流更多
BKTI
多$55.6M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-21.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $21.5M | $30.3M |
| 净利润 | $4.2M | $-67.1M |
| 毛利率 | 50.5% | — |
| 营业利润率 | 19.7% | -190.0% |
| 净利率 | 19.7% | -221.3% |
| 营收同比 | 20.0% | 43.0% |
| 净利润同比 | 15.6% | -31.2% |
| 每股收益（稀释后） | $1.06 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BKTIRGNX
| Q4 25 | $21.5M | $30.3M | ||
| Q3 25 | $24.4M | $29.7M | ||
| Q2 25 | $21.2M | $21.4M | ||
| Q1 25 | $19.1M | $89.0M | ||
| Q4 24 | $17.9M | $21.2M | ||
| Q3 24 | $20.2M | $24.2M | ||
| Q2 24 | $20.3M | $22.3M | ||
| Q1 24 | — | $15.6M |
净利润BKTIRGNX
| Q4 25 | $4.2M | $-67.1M | ||
| Q3 25 | $3.4M | $-61.9M | ||
| Q2 25 | $3.7M | $-70.9M | ||
| Q1 25 | $2.1M | $6.1M | ||
| Q4 24 | $3.7M | $-51.2M | ||
| Q3 24 | $2.4M | $-59.6M | ||
| Q2 24 | $1.7M | $-53.0M | ||
| Q1 24 | — | $-63.3M |
毛利率BKTIRGNX
| Q4 25 | 50.5% | — | ||
| Q3 25 | 49.9% | — | ||
| Q2 25 | 47.4% | — | ||
| Q1 25 | 47.0% | — | ||
| Q4 24 | 41.2% | 70.2% | ||
| Q3 24 | 38.8% | 48.8% | ||
| Q2 24 | 37.3% | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率BKTIRGNX
| Q4 25 | 19.7% | -190.0% | ||
| Q3 25 | 19.8% | -176.3% | ||
| Q2 25 | 18.9% | -296.3% | ||
| Q1 25 | 15.3% | 13.6% | ||
| Q4 24 | 12.3% | -242.1% | ||
| Q3 24 | 12.9% | -256.6% | ||
| Q2 24 | 10.0% | -251.3% | ||
| Q1 24 | — | -408.8% |
净利率BKTIRGNX
| Q4 25 | 19.7% | -221.3% | ||
| Q3 25 | 14.1% | -208.3% | ||
| Q2 25 | 17.7% | -331.8% | ||
| Q1 25 | 11.2% | 6.8% | ||
| Q4 24 | 20.4% | -241.3% | ||
| Q3 24 | 11.7% | -246.3% | ||
| Q2 24 | 8.2% | -237.7% | ||
| Q1 24 | — | -405.4% |
每股收益（稀释后）BKTIRGNX
| Q4 25 | $1.06 | $-1.30 | ||
| Q3 25 | $0.87 | $-1.20 | ||
| Q2 25 | $0.96 | $-1.38 | ||
| Q1 25 | $0.55 | $0.12 | ||
| Q4 24 | $0.96 | $-0.99 | ||
| Q3 24 | $0.63 | $-1.17 | ||
| Q2 24 | $0.47 | $-1.05 | ||
| Q1 24 | — | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $22.8M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $44.7M | $102.7M |
| 总资产 | $63.8M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BKTIRGNX
| Q4 25 | $22.8M | $230.1M | ||
| Q3 25 | $21.5M | $274.2M | ||
| Q2 25 | $11.9M | $323.3M | ||
| Q1 25 | $8.9M | $267.9M | ||
| Q4 24 | $7.1M | $234.7M | ||
| Q3 24 | $4.2M | $255.5M | ||
| Q2 24 | $3.0M | $290.4M | ||
| Q1 24 | — | $338.7M |
股东权益BKTIRGNX
| Q4 25 | $44.7M | $102.7M | ||
| Q3 25 | $41.0M | $161.5M | ||
| Q2 25 | $36.8M | $213.7M | ||
| Q1 25 | $32.4M | $274.2M | ||
| Q4 24 | $29.8M | $259.7M | ||
| Q3 24 | $26.0M | $301.4M | ||
| Q2 24 | $23.4M | $348.3M | ||
| Q1 24 | — | $390.7M |
总资产BKTIRGNX
| Q4 25 | $63.8M | $453.0M | ||
| Q3 25 | $66.9M | $525.2M | ||
| Q2 25 | $60.4M | $581.0M | ||
| Q1 25 | $56.1M | $490.9M | ||
| Q4 24 | $51.5M | $466.0M | ||
| Q3 24 | $46.4M | $519.1M | ||
| Q2 24 | $48.9M | $569.4M | ||
| Q1 24 | — | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.0M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $2.8M | $-52.8M |
| 自由现金流率自由现金流/营收 | 13.2% | -174.0% |
| 资本支出强度资本支出/营收 | 0.7% | 1.7% |
| 现金转化率经营现金流/净利润 | 0.71× | — |
| 过去12个月自由现金流最近4个季度 | $18.4M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流BKTIRGNX
| Q4 25 | $3.0M | $-52.3M | ||
| Q3 25 | $10.4M | $-56.0M | ||
| Q2 25 | $3.9M | $-49.3M | ||
| Q1 25 | $2.1M | $33.6M | ||
| Q4 24 | $3.8M | $-31.6M | ||
| Q3 24 | $5.7M | $-40.5M | ||
| Q2 24 | $4.1M | $-45.5M | ||
| Q1 24 | — | $-55.5M |
自由现金流BKTIRGNX
| Q4 25 | $2.8M | $-52.8M | ||
| Q3 25 | $10.1M | $-56.5M | ||
| Q2 25 | $3.7M | $-49.7M | ||
| Q1 25 | $1.8M | $32.6M | ||
| Q4 24 | $3.4M | $-32.7M | ||
| Q3 24 | $5.2M | $-40.9M | ||
| Q2 24 | $3.9M | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率BKTIRGNX
| Q4 25 | 13.2% | -174.0% | ||
| Q3 25 | 41.3% | -189.9% | ||
| Q2 25 | 17.3% | -232.8% | ||
| Q1 25 | 9.6% | 36.6% | ||
| Q4 24 | 19.2% | -154.2% | ||
| Q3 24 | 25.8% | -168.9% | ||
| Q2 24 | 19.2% | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度BKTIRGNX
| Q4 25 | 0.7% | 1.7% | ||
| Q3 25 | 1.5% | 1.7% | ||
| Q2 25 | 1.2% | 1.8% | ||
| Q1 25 | 1.4% | 1.2% | ||
| Q4 24 | 2.0% | 5.1% | ||
| Q3 24 | 2.2% | 1.3% | ||
| Q2 24 | 1.0% | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率BKTIRGNX
| Q4 25 | 0.71× | — | ||
| Q3 25 | 3.04× | — | ||
| Q2 25 | 1.04× | — | ||
| Q1 25 | 0.98× | 5.53× | ||
| Q4 24 | 1.04× | — | ||
| Q3 24 | 2.40× | — | ||
| Q2 24 | 2.46× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BKTI
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
